When WNY Ovarian Cancer Project co-founder Kathleen Maxian was diagnosed with ovarian cancer, she felt overwhelmed by the amount of negative statistics and information she found on the internet. It took a long 6 months until she met a long-term ovarian cancer survivor who showed her survival was possible. Now a 6-year survivor, Kathleen says … Continued
Several promising advances in the treatment of ovarian cancer were presented at this year’s annual meeting of the American Society of Clinical Oncologists (ASCO). Below is a report from one of our Research Advocates, Katie Hoody. Click the plus sign to read Katie's report.
(6/19/15) OCRF recently welcomed three new members to the Scientific Advisory Committee (SAC), our world-class group of leaders in the ovarian cancer field who review and approve all OCRF research grants. Dineo Khabele, M.D., of Vanderbilt University Medical Center, Celeste Leigh Pearce, Ph.D., M.P.H., of University of Michigan, and Daniel J. Powell, Jr., Ph.D., of … Continued
(June 19, 2015) In a recent study, funded in part by OCRF grants to Dr. Simon Gayther and Dr. Andrew Berchuck, researchers have made important breakthroughs toward understanding the risk and growth of a certain kind of ovarian cancer, known as mucinous ovarian carcinoma, or MOC. The international study involving 1,644 women with MOC and … Continued
(June 18, 2015) A team of researchers, including OCRF grantees Juan Cubillos-Ruiz, PhD, and Alfredo Perales-Puchalt, MD, have discovered how ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor. The findings are published in the June 11 issue of Cell. A therapy that … Continued
(June 17, 2015) Researchers at MD Anderson Cancer Center in Houston have identified a new class of gene mutations that may contribute to outcomes in the treatment of ovarian cancer. Research on the gene family known as ADAMTS could open up a new genetic avenue for the design of ovarian cancer therapies. The findings were … Continued
(June 5, 2015) The Society of Gynecologic Oncology has posted three short videos on YouTube that highlight some of the ovarian cancer research findings presented at the American Society of Clinical Oncology annual meeting last week. Click here to watch the videos, which highlight the results of a number of ovarian cancer clinical trials.
When Turn The Towns Teal®’s founder Gail MacNeil was diagnosed with ovarian cancer almost eighteen years ago, she realized the need for ovarian cancer awareness and saw that nothing was being done that focused solely on ovarian cancer awareness. Turn The Towns Teal grew out of this idea, and has since become a national campaign … Continued
(May 28, 2015) In an effort to study treatment options for high-grade serous ovarian cancer, scientists from the University of Queensland and Sydney’s Millennium Institute collected DNA from 92 patients to find out what makes those cells so resistant to chemotherapy. OCRF Scientific Advisory Committee members Ronny Drapkin, MD, PhD, and Ernst Lengyel, MD, PhD, … Continued
(May 28, 2015) A recent study performed in the UK and New Zealand revealed that having chemotherapy treatments before and after surgery is associated with a higher quality of life when compared to those who undergo surgery before chemotherapy. The study, which included 550 women with Stage III or IV ovarian cancer, concluded that shrinking … Continued
Introducing the 2015 Ovarian Cancer National Conference Rosalind Franklin Excellence in Ovarian Cancer Research Award winner: Beth Karlan, MD. The Rosalind Franklin Excellence in Ovarian Cancer Research Award is named for the molecular biologist Dr. Rosalind Elsie Franklin, who played a vital role in discovering the structure of DNA. Her career was cut short in 1958 when she died of ovarian cancer at age 37. Throughout her life, she was a committed researcher; this award honors an individual who continues her legacy of excellence. Beth Karlan, MD is the Director of the Cedars-Sinai Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Director of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, and Director of the Gilda Radner Hereditary Cancer Program. Click the plus sign to read more.
The Cindy Melancon Spirit Award commends and honors an individual for his or her commitment to the ovarian cancer community. The award is named after Cindy Melancon, a founder of the Ovarian Cancer National Alliance and creator of the CONVERSATIONS! newsletter. The award has been given to many excellent ovarian cancer leaders throughout the years. Carey Fitzmaurice, survivor since 2006, is the founder of Teal Toes, a national non-profit organization dedicated to educating women about the symptoms of ovarian cancer. Since 2007, Teal Toes has been sending out symptom cards, and promoting education and awareness through its website and social media. Click the plus sign to read more.
Get email updates about research news, action alerts, and ways to join the fight.
